Anthony Nicholas Karnezis, M.D., P.h.D.

Associate Professor, Department of Pathology

To see if Anthony Nicholas Karnezis is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).




Locations and Contact

Pathology Building

4400 V St.
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Referral Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Clinical Interests

Dr. Karnezis is the Lead gynecologic pathologist, Director of the Breast and Gynecologic Pathology Fellowship. He is a contributing author to the World Health Organization (WHO) Classification of Tumors of the Female Reproductive Tract and WHO Classification of Paediatric Tumours.

Research/Academic Interests

Dr. Karnezis has broad research interests ranging from basic molecular and cell biology, drug studies in pre-clinical mouse models of cancer, clinical diagnostics, molecular pathology of human cancers, diagnostic biomarker identification, and clinical outcome studies. He has a longstanding interest in the TP53 and RB tumor suppressor pathways and how mutations in these and other pathways regulate tumour pathogenesis, differentiation, histomorphology, and responses to targeted therapies.


Anatomic Pathology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.A., Northwestern University, Evanston IL 1992

Medical School

M.D., Northwestern University, Feinberg School of Medicine, Chicago IL 2002

Other School

Ph.D., Albert Einstein College of Medicine of Yeshiva University, Bronx NY 2002


Anatomical Pathology, UC San Francisco, San Francisco CA 2002-2004


Postdoctoral Research Fellowships, UC San Francisco, San Francisco CA 2005-2012


Surgical Pathology Fellowship, UC San Francisco, San Francisco CA 2012-2013


Molecular and Gynecologic Pathology Fellowship, University of British Columbia, Vancouver, BC, Canada 2013-2016

Best Oral Presentation, Canadian Conference on Ovarian Cancer Research, 2014

Travel Award, Canadian Conference on Ovarian Cancer Research, 2014

Resident Teaching Award, UCSF Department of Pathology, 2013

Alpha Omega Alpha National Medical Honor Society, 1995

Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F. Tubo-Ovarian. Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles. Int J Gynecol Pathol. 2018 Jul 27; doi:10.1097/PGP.0000000000000538. PMID:30059451.

Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer. 2018 Jul 27; doi:10.1038/s41416-018-0187-6. PMID:30050154.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson  BH, Shah SP. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer Cell. 2018 Jun 14;173(7):1755-1769.e22. doi:10.1016/j.cell.2018.03.073. Epub 2018 May 10. PMID:29754820.

Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, Rathmell WK, Weissman BE. High Frequency of Ovarian Cyst Development in Vhl(2B/+); Snf5(+/-) Mice. Am J Pathol. 2018 Jul;188(7):1510-1516. doi:10.1016/j.ajpath.2018.03.010. Epub 2018 Apr 22. PMID:29684361.

Wang Y, Karnezis AN, Magrill J, Tessier-Cloutier B, Lum A, Senz J, Gilks CB, McCluggage WG, Huntsman DG, Kommoss F. DICER1 hot-spot mutations in ovarian gynandroblastoma. Histopathology. 2018 Aug;73(2):306-313. doi:10.1111/his.13630. Epub 2018 Jun 5. PMID:29660837.

Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clin Cancer Res. 2018 Apr 15;24(8):1932-1943. doi:10.1158/1078-0432.CCR-17-1928. Epub 2018 Feb 9. PMID:29440177.

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018 May 1;29(5):1180-1188. doi:10.1093/annonc/mdy058. PMID:29432521.

Nazeran T, Cheng AS, Karnezis AN, Tinker AV, Gilks CB. Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome. Int J Gynecol Pathol. 2018 Feb 5; doi:10.1097/PGP.0000000000000489. PMID:29406447.

Garg K, Karnezis AN, Rabban JT. Uncommon hereditary gynecological tumor syndromes: pathological features in tumors that may predict risk for a germline mutation. Pathology. 2018 Feb;50(2):238-256. doi:10.1016/j.pathol.2017.10.009. Epub 2018 Jan 17. PMID:29373116.

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 2017 Oct 14;3(4):279-293. doi:10.1002/cjp2.82. PMID:29085668.